Gabapentin for the treatment of painful diabetic neuropathy: Dosing to achieve optimal clinical response

British Journal of Diabetes and Vascular Disease

Volumn 4, Issue 3, 2004, Pages 173-178

  Gómez Pérez, Francisco J ^a   Perez Monteverde, Armando ^b   Nascimento, Osvaldo ^c   Aschner, Pablo ^d   Tagle, Marino ^e   Fichtner, Klaus ^f   Subbiah, Ponni ^g   Mustiya, Elizabeth M ^g   Parsons, Bruce ^g  

^a Departamente de Genetica   (Mexico)

^b Centro Medico Docente La Trinidad   (Venezuela)

^c FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

^d Future Surgeons Chapter   (Colombia)

^e Hospital Regional Teodoro Maldonado Carbo   (Ecuador)

^f Latin America CRO Mmatiss   (Mexico)

^g PFIZER INC   (United States)

Author keywords

Dose Titration; Gabapentin; Neuropathic pain

Indexed keywords

GABAPENTIN; PLACEBO;

ADULT; ANALGESIC ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEUROPATHY; DIZZINESS; DOSE CALCULATION; DOSE RESPONSE; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NEUROPATHIC PAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; PAIN ASSESSMENT; PHASE 4 CLINICAL TRIAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SLEEP; SOMNOLENCE; TITRIMETRY; VISUAL ANALOG SCALE;

EID: 3242759233     PISSN: 14746514     EISSN: None     Source Type: Journal    
DOI: 10.1177/14746514040040030601     Document Type: Article

References (44)

1. Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med 1997;14(suppl 5):S1-S85.
2. Harris MI, Flegal KM, Cowie CC et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 1998;21:518-24.
3. Mokdad AH, Ford ES, Bowman BA et al. Diabetes trends in the U.S.: 1990-1998. Diabetes Care 2000;23:1278-83.
4. Mokdad AH, Ford ES, Bowman BA et al. The continuing increase of diabetes in the U.S. Diabetes Care 2001;24:412.
5. Harris MI, Flegal KM, Cowie CC et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 1998;21:518-24.
6. Albala C, Vio F, Kain J, Uauy R. Nutrition transition in Latin America: the case of Chile. Nutr Rev 2001;59:170-6.
7. Uauy R, Albala C, Kain J. Obesity trends in Latin America: transiting from under- to overweight. J Nutr 2001;131:893S-899S.
8. Aschner P. Diabetes trends in Latin America. Diabetes Metab Res Rev 2002;18(suppl 3):S27-31.
9. Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med 1997;14(suppl 5):S1-85.
10. Pirart J. [Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973 (3rd and last part) (author's transl)]. Diabete Metab 1977;3:245-56.
11. Dyck PJ, Kratz KM, Karnes JL et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology 1993;43:817-24.
12. Jensen PG, Larson JR. Management of painful diabetic neuropathy. Drugs Aging 2001;18:737-49.
13. Tremont-Lukats IW, Megeff C, Backonja MM. Anticonvulsants for neuropathic pain syndromes: mechanisms of action and place in therapy Drugs 2000;60:1029-52.
14. Rull JA, Quibrera R, Gonzalez-Millan H, Lozano Castaneda O. Symptomatic treatment of peripheral diabetic neuropathy with carbamazepine (Tegretol): double blind crossover trial. Diabetologia 1969;5: 215-18.
15. Gomez-Perez FJ, Choza R, Rios JM et al. Nortriptyline-fluphenazine vs. carbamazepine in the symptomatic treatment of diabetic neuropathy. Arch Med Res 1996;27:525-9.
16. Backonja M, Beydoun A, Edwards KR et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 1998;280:1831-6.
17. Rowbotham M, Harden N, Stacey B, Bernstein F, Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 1998;280:1837-42.
18. Eisenberg E, Lurie Y, Braker C, Daoud D, Ishay A. Lamotrigine reduces painful diabetic neuropathy: a randomized, controlled study. Neurology 2001;57:505-09.
19. Rice AS, Maton S. Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study. Pain 2001;94:215-24.
20. Serpell MG. Gabapentin in neuropathic pain syndromes: a randomised, double-blind, placebo-controlled trial. Pain 2002;99:557-66.
21. Nicholson B. Gabapentin use in neuropathic pain syndromes. Acta Neurol Scand 2000;101:359-71.
22. Taylor CP, Gee NS, Su TZ et al. A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res 1998;29:233-49.
23. Goldlust A, Su TZ, Welty DF, Taylor CD, Oxender DL. Effects of anticonvulsant drug gabapentin on the enzymes in metabolic pathways of glutamate and GABA. Epilepsy Res 1995;22(1):1-11.
24. Gee NS, Brown JP, Dissanayake VU, Offord J, Thurlow R, Woodruff GN. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel. J Biol Chem 1996;271:5768-76.
25. Stefani A, Spadoni F, Bernardi G. Gabapentin inhibits calcium currents in isolated rat brain neurons. Neuropharmacology 1998;37(1):83-91.
26. Block F. [Gabapentin therapy for pain]. Nervenarzt 2001;72(2):69-77.
27. Gotz E, Feuerstein TJ, Lais A, Meyer DK. Effects of gabapentin on release of gamma-aminobutyric acid from slices of rat neostriatum. Arzneimittelforschung 1993;43:636-8.
28. Petroff OA, Rothman DL, Behar KL, Lamoureux D, Mattson RH. The effect of gabapentin on brain gamma-aminobutyric acid in patients with epilepsy. Ann Neurol 1996;39(1):95-9.
29. Beydoun A, Uthman BM, Sackellares JC. Gabapentin: pharmacokinetics, efficacy, and safety. Clin Neuropharmacol 1995;18:469-81.
30. Boyd RA, Turck D, Abel RB, Sedman AJ, Bockbrader HN. Effects of age and gender on single-dose pharmacokinetics of gabapentin. Epilepsia 1999;40:474-9.
31. UK Gabapentin Study Group. Gabapentin in partial epilepsy. Lancet 1990;335:1114-17.
32. US Gabapentin Study Group No. 5. Gabapentin as add-on therapy in refractory partial epilepsy: a double-blind, placebo-controlled, parallel-group study. Neurology 1993;43:2292-8.
33. Anhut H, Ashman P, Feuerstein TJ, Sauermann W, Saunders M, Schmidt B. Gabapentin (Neurontin) as add-on therapy in patients with partial seizures: a double-blind, placebo-controlled study. The International Gabapentin Study Group. Epilepsia 1994;35:795-801.
34. Laird MA, Gidal BE. Use of gabapentin in the treatment of neuropathic pain. Ann Pharmacother 2000;34:802-07.
35. NFO Worldgroup Report to Pfizer, 2002.
36. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30:473-83.
37. Rosenberg JM, Harrell C, Ristic H, Werner RA, de Rosayro AM. The effect of gabapentin on neuropathic pain. Clin J Pain 1997;13:251-5.
38. Morello CM, Leckband SG, Stoner CP, Moorhouse DF, Sahagian GA. Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Arch Intern Med 1999;159:1931-7.
39. Perez HE, Sanchez GF. Gabapentin therapy for diabetic neuropathic pain. Am J Med 2000;108:689.
40. Gorson KC, Schott C, Herman R, Ropper AH, Rand WM. Gabapentin in the treatment of painful diabetic neuropathy: a placebo controlled, double blind, crossover trial. J Neurol Neurosurg Psychiatry 1999;66:251-2.
41. Hemstreet B, Lapointe M. Evidence for the use of gabapentin in the treatment of diabetic peripheral neuropathy. Clin Ther 2001;23:520-31.
42. McLean ML. Gabapentin in the management of convulsive disorders. Epilepsia 40(suppl 6):S39-50; discussion S73-4. Review 1999.
43. Dougherty JA, Rhoney DH. Gabapentin: a unique anti-epileptic agent. Neurol Res 2001;23:821-9.
44. Package insert for Neurontin. 2002.